Pet Products

PUBLISHER: 360iResearch | PRODUCT CODE: 2088739

PUBLISHER: 360iResearch | PRODUCT CODE: 2088739

CBD Pet Market by Product Type, Pet Type, Source, Application, Distribution Channel - Global Forecast 2026-2032

PUBLISHED: July 14, 2026

PAGES: 194 Pages

DELIVERY TIME: 1-2 business days

ADD TO COMPARE

SELECT AN OPTION

List of Tables

The CBD Pet Market is projected to grow by USD 1,016.09 million at a CAGR of 15.51% by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 370.24 million
Estimated Year [2026]	USD 418.34 million
Forecast Year [2032]	USD 1,016.09 million
CAGR (%)	15.51%

CBD Pet Market Introduction

The CBD pet market is evolving from a novelty category into a regulated, evidence-sensitive segment of the broader pet wellness economy. Demand is concentrated in hemp-derived pet products such as CBD oil for dogs, soft chews, topical balms, and functional treats positioned around calm behavior, mobility support, aging pet care, and everyday wellness. Growth is being shaped by the same macro forces driving premium pet care: humanization of pets, higher spending on companion animal health, direct-to-consumer commerce, and rising interest in plant-derived wellness ingredients.

Regulatory clarity remains the defining constraint. In the United States, the 2018 Farm Bill removed hemp with no more than 0.3% delta-9 THC from the federal controlled substances list, but the U.S. FDA has not approved CBD for use in animal food, feed, or pet supplements. This creates a market where compliant labeling, third-party testing, contaminant control, transparent hemp sourcing, and conservative claims management are essential for credible CBD pet brands.

Transformative Shifts in the CBD Pet Landscape

The most important shift in the CBD pet landscape is the movement from informal wellness products to professionally manufactured, quality-assured pet formulations. Pet owners increasingly expect certificates of analysis, THC transparency, batch traceability, and clear dosing guidance, while retailers are reducing exposure to brands that rely on unsubstantiated disease-treatment claims. This has raised the competitive bar for pet CBD companies and strengthened demand for GMP-aligned production, clean-label ingredients, and veterinarian-informed product development.

Channel dynamics are also changing. E-commerce and subscription models help brands educate consumers and manage repeat purchases, while specialty pet retailers and independent pet stores remain critical for trust-based discovery. At the same time, regulatory divergence across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa is pushing companies toward country-specific compliance playbooks rather than one-size-fits-all international expansion.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a practical differentiator in the CBD pet market by improving product development, customer education, supply chain control, and compliance monitoring. AI-enabled analytics can identify consumer search intent around CBD oil for dogs, hemp pet treats, calming chews, topical balms, and senior pet wellness, allowing brands to create evidence-aware content without crossing into prohibited drug claims. Machine learning can also support inventory planning for recurring-use products and optimize fulfillment across direct-to-consumer, marketplace, and specialty retail channels.

The cumulative impact is most visible in quality and risk management. AI tools can help screen certificates of analysis, flag inconsistent cannabinoid potency, detect contaminant trends, monitor adverse-event language in customer reviews, and identify labeling risks across jurisdictions. For responsible industry leaders, AI should augment-not replace-veterinary expertise, regulatory review, and laboratory verification.

Key Regional Insights Across CBD Pet Markets

North America remains the most commercially developed region for CBD pet products, led by the United States and supported by Canada's federally regulated cannabis framework. U.S. demand benefits from high pet ownership, established e-commerce infrastructure, and broad consumer familiarity with hemp-derived wellness products, although FDA restrictions on CBD in animal products continue to limit permissible claims. Canada offers a clearer national cannabis regime, but veterinary access and product authorization pathways remain tightly controlled.

Europe is characterized by strong consumer interest in pet wellness but complex regulatory fragmentation. The European Union treats CBD in many ingestible contexts through Novel Food considerations, while individual countries apply different controls to cannabinoids, THC thresholds, veterinary products, and marketing language. Asia-Pacific is promising over the long term because of rising pet humanization in China, Japan, South Korea, Australia, and India, yet cannabinoid regulations are often restrictive and require cautious market entry. Latin America shows emerging opportunity in Brazil and Mexico as cannabis policy evolves, while the Middle East and Africa remain selective markets where legal status, import controls, veterinary product rules, and cultural attitudes toward cannabis-derived ingredients strongly influence commercialization.

Key Group Insights for Strategic CBD Pet Expansion

Within ASEAN, CBD pet commercialization is still limited by strict narcotics laws in several member states and uneven acceptance of cannabis-derived consumer products, making compliant importation, THC controls, and consumer education essential. The GCC is even more conservative; companies evaluating Gulf markets must prioritize legal due diligence, customs rules, veterinary product restrictions, and zero-tolerance approaches in some jurisdictions before considering pet CBD products.

The European Union offers scale but demands rigorous regulatory assessment, especially around Novel Food status, THC limits, and member-state enforcement practices. BRICS markets are highly diverse: China and India provide large pet population potential but tight cannabis controls, Brazil is gradually becoming more relevant as medical cannabis regulation matures, Russia remains constrained, and South Africa provides comparatively more visible cannabis policy discussion. G7 countries collectively represent advanced pet care spending, strong e-commerce adoption, and higher expectations for product safety, traceability, and substantiated labeling. NATO membership does not create a CBD regulatory framework, but many NATO economies overlap with developed pet care markets where compliance, batch documentation, and conservative claims are decisive.

Key Country Insights for CBD Pet Growth

The United States is the central demand engine for CBD pet products, but companies must operate with awareness that FDA has not approved CBD as an animal feed additive or pet supplement ingredient. Canada's regulated cannabis system creates a structured environment, while Mexico and Brazil represent longer-term Latin American opportunities as cannabis policy and veterinary wellness channels mature. In Europe, the United Kingdom, Germany, France, Italy, and Spain show strong premium pet care demand, but CBD pet brands must navigate Novel Food rules, veterinary medicine classifications, national THC limits, and country-specific advertising standards. Russia presents higher regulatory and geopolitical complexity.

In Asia-Pacific, China and India have major pet population potential but restrictive cannabinoid pathways, making near-term opportunities more limited for ingestible CBD pet products. Japan and South Korea require careful attention to THC controls and import standards, while Australia combines high pet spending with a more medicalized cannabis framework that constrains over-the-counter CBD pet positioning. Across all countries, the most defensible approach is localized compliance, third-party testing, transparent hemp sourcing, adverse-event monitoring, and claims focused on general wellness rather than disease treatment.

Actionable Recommendations for CBD Pet Leaders

Industry leaders should build trust before scale. The strongest CBD pet brands will invest in third-party laboratory testing, batch-specific certificates of analysis, THC and contaminant controls, transparent hemp sourcing, and clear serving guidance by animal size. Marketing should avoid disease-treatment claims and instead emphasize responsible pet wellness positioning supported by quality documentation and veterinary review.

Companies should also create region-specific regulatory playbooks, maintain adverse-event monitoring, and use AI-enabled compliance tools to review labeling, website copy, customer reviews, and marketplace listings. Partnerships with veterinarians, specialty pet retailers, and reputable contract manufacturers can improve credibility, while subscription programs and education-led content can strengthen retention in CBD oil, chews, treats, and topical pet products.

Research Methodology

This executive summary is based on a structured review of established regulatory facts, publicly available government guidance, recognized cannabis policy frameworks, pet care industry dynamics, and observable commercial practices in hemp-derived pet wellness. Core references include the U.S. 2018 Farm Bill framework for hemp, the FDA's position that CBD is not approved for animal food or pet supplements, Canada's federal cannabis regulatory structure, and the European Union's Novel Food approach to CBD.

The analysis triangulates regional regulation, pet ownership and premiumization trends, retail channel behavior, consumer search demand, veterinary oversight considerations, and product quality requirements. Insights are presented conservatively to avoid unverified medical claims, market sizing, market share, or forecasting, and to reflect the compliance-sensitive nature of the CBD pet market.

Conclusion

The CBD pet market has durable long-term potential, but category development depends on trust, regulatory discipline, and product quality rather than aggressive claims. Pet owners are interested in hemp-derived wellness solutions, especially for dogs and aging companion animals, but regulators continue to scrutinize CBD use in ingestible animal products.

Brands that combine compliant marketing, verified testing, transparent sourcing, AI-supported risk management, and veterinarian-informed education will be best positioned to compete as the category matures across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.

Product Code: MRR-B9334AD6C1DD

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
- 2.2.1. Primary Research
- 2.2.2. Secondary Research
2.3. Research Framework
- 2.3.1. Qualitative Analysis
- 2.3.2. Quantitative Analysis
2.4. Market Size Estimation
- 2.4.1. Top-Down Approach
- 2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
- 4.2.1. Supply-Side Analysis
- 4.2.2. Demand-Side Analysis
- 4.2.3. Stakeholder Analysis
4.3. Market Dynamics
- 4.3.1. Key Drivers
- 4.3.2. Key Restraints
- 4.3.3. Key Opportunities
- 4.3.4. Key Challenges
4.4. Porter's Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
- 4.6.1. Near-Term Market Outlook (0-2 Years)
- 4.6.2. Medium-Term Market Outlook (3-5 Years)
- 4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. CBD Pet Market, by Product Type

7.1. CBD Oils & Tinctures
- 7.1.1. Full-Spectrum CBD Oils
- 7.1.2. Broad-Spectrum CBD Oils
- 7.1.3. CBD Isolate Oils
7.2. CBD Edibles for Pets
7.3. CBD Topicals
- 7.3.1. CBD Balms
- 7.3.2. CBD Creams
- 7.3.3. CBD Sprays
7.4. CBD Powder
7.5. CBD Dental Chews

8. CBD Pet Market, by Pet Type

8.1. Cats
8.2. Dogs
8.3. Horses
8.4. Hamsters

9. CBD Pet Market, by Source

9.1. Hemp-Derived CBD
9.2. Marijuana-Derived CBD

10. CBD Pet Market, by Application

10.1. Anxiety Management
10.2. Pain Management
- 10.2.1. Arthritis Pain
- 10.2.2. Joint Pain
10.3. Seizure & Epilepsy Management
10.4. Skin Conditions
- 10.4.1. Dermatitis
- 10.4.2. Allergies
- 10.4.3. Itching
10.5. Digestive Health
10.6. Inflammation Reduction

11. CBD Pet Market, by Distribution Channel

11.1. Online
11.2. Offline

12. CBD Pet Market, by Region

12.1. Asia-Pacific
12.2. North America
12.3. Latin America
12.4. Europe
12.5. Middle East
12.6. Africa

13. CBD Pet Market, by Group

13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO

14. CBD Pet Market, by Country

14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea

15. Competitive Landscape

15.1. Market Concentration Analysis, 2025
- 15.1.1. Concentration Ratio (CR)
- 15.1.2. Herfindahl Hirschman Index (HHI)
15.2. Recent Developments & Impact Analysis, 2025
15.3. Product Portfolio Analysis, 2025
15.4. Benchmarking Analysis, 2025

16. Company Profiles

16.1. Balanced Health Botanicals
16.2. Canna-Biscuits
16.3. Canna-Pet LLC
16.4. CBD American Shaman
16.5. CBD Living
16.6. CBDfx
16.7. cbdMD, Inc.
16.8. Charlotte's Web, Inc.
16.9. Cornbread Hemp
16.10. Creating Brighter Days
16.11. CV Sciences, Inc.
16.12. Elixinol Wellness Ltd
16.13. Fomo Bones
16.14. Green Roads
16.15. HempMy Pet
16.16. HolistaPet
16.17. Honest Paws LLC
16.18. Innovet Pet
16.19. Joy Organics
16.20. King Kanine
16.21. Lazarus Naturals
16.22. Medterra CBD, LLC
16.23. NuLeaf Naturals, LLC
16.24. Pet Releaf
16.25. Petly CBD
16.26. Royal CBD
16.27. Swedencare AB
16.28. The Anxious Pet
16.29. Veritas Farms
16.30. Verma Farms